



RON CHAPMAN, MD, MPH  
Director & State Health Officer

State of California—Health and Human Services Agency  
California Department of Public Health



EDMUND G. BROWN JR.  
Governor

OFFICE OF AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2013-14

Date: September 6, 2013

TO: LOCAL ADAP COORDINATORS  
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF DOLUTEGRAVIR (TIVICAY) TO THE ADAP FORMULARY

**Effective September 9, 2013**, dolutegravir (**Tivicay**) 50mg tablets will be added to the ADAP formulary. Dolutegravir is a new antiretroviral (ARV) drug of the integrase-inhibitor class which was approved by the U.S. Food and Drug Administration on August 12, 2013 for treatment in both treatment-naïve and treatment-experienced individuals infected with the human immunodeficiency virus (HIV). It is usually dosed once per day and must be used in combination with at least two other ARVs for treatment of HIV.

With the addition of dolutegravir, ADAP has 185 drugs on the formulary.

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact me at (916) 44-5943.

Celia Banda-Brown, Chief  
ADAP Section  
Office of AIDS